Coherus Files On-Body Pegfilgrastim, Says ‘People Talk’ On Potential Rivals
Amgen’s Neulasta Onpro Device Continues To Hold More Than 40% Of Market
Having previously underlined that it would not tell the market the exact moment it filed its proposed biosimilar pegfilgrastim on-body injector device, Coherus BioSciences has now confirmed a filing was completed late last year.
You may also be interested in...
Generics Bulletin looks back at a selection of the most significant legal stories from 2022, including a major victory in the UK on the Eliquis blood thinner giant and continued action on generic label carve outs, which has the potential to reverberate through the US industry.
Teva’s partnership with MedinCell for long-acting injectable products, first penned a decade ago, is beginning to gather steam, as another candidate entered the clinic ahead of a potential first approval in the coming months.
Following Fresenius Kabi’s approval in mid-December for the eighth and latest biosimilar Humira (adalimumab) product, the company’s senior vice president for biosimilars in the US spoke to Generics Bulletin about how it can stand out from the pack and why it is confident that it can succeed.